Cryer Philip E
Division of Endocrinology, Metabolism and Lipid Research, General Clinical Research Center, and Diabetes Research and Training Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Clin Invest. 2006 Jun;116(6):1470-3. doi: 10.1172/JCI28735.
A reduced sympathoadrenal response, induced by recent antecedent hypoglycemia, is the key feature of hypoglycemia-associated autonomic failure (HAAF) and, thus, the pathogenesis of iatrogenic hypoglycemia in diabetes. Understanding of the mechanism(s) of that reduced response awaits new insight into its basic molecular, cellular, organ, and whole-body physiology and pathophysiology in experimental models. In this issue of the JCI, McCrimmon and colleagues report that application of urocortin I (a corticotrophin-releasing factor receptor-2 agonist) to the ventromedial hypothalamus reduces the glucose counterregulatory response to hypoglycemia in rats (see the related article beginning on page 1723). Thus, hypothalamic urocortin I release during antecedent hypoglycemia is, among other possibilities, a potential mechanism of HAAF.
近期发生的低血糖所诱发的交感肾上腺反应减弱,是低血糖相关自主神经功能衰竭(HAAF)的关键特征,因此也是糖尿病医源性低血糖的发病机制。要了解这种反应减弱的机制,还需在实验模型中对其基础分子、细胞、器官及全身生理学和病理生理学有新的认识。在本期《临床研究杂志》中,麦克里蒙及其同事报告称,将尿皮质素I(一种促肾上腺皮质激素释放因子受体2激动剂)应用于大鼠腹内侧下丘脑,可降低大鼠对低血糖的葡萄糖反向调节反应(见第1723页开始的相关文章)。因此,在前驱性低血糖期间下丘脑释放尿皮质素I,在其他可能性中,是HAAF的一种潜在机制。